These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 5938056)

  • 21. Allopurinol in the treatment of hyperuricemia and gout.
    Healey LA
    Northwest Med; 1966 May; 65(5):400-3. PubMed ID: 5930946
    [No Abstract]   [Full Text] [Related]  

  • 22. Allopurinol in the treatment of uraemic patients with gout.
    Wilson JD; Simmonds HA; North JD
    Ann Rheum Dis; 1967 Mar; 26(2):136-42. PubMed ID: 6023695
    [No Abstract]   [Full Text] [Related]  

  • 23. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic approach to the maintenance of urate homeostasis.
    Kelley WN
    Nephron; 1975; 14(1):99-115. PubMed ID: 1091870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allopurinol in the management of gout.
    Newton DR
    Ann Phys Med; 1966 Aug; 8(7):235-41. PubMed ID: 5918264
    [No Abstract]   [Full Text] [Related]  

  • 26. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.
    Rozenberg S; Roche B; Dorent R; Koeger AC; Borget C; Wrona N; Bourgeois P
    Rev Rhum Engl Ed; 1995 May; 62(5):392-4. PubMed ID: 7655872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical findings and therapy of gout with special reference to the metabolic effects of sulfinpyrazone (Anturan) and allopurinol (Zyloric)].
    Günther R; Knapp E
    Wien Klin Wochenschr; 1969 Nov; 81(45):817-20. PubMed ID: 5362152
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of allopurinol on gouty and non-gouty uric acid nephropathy.
    Ogryzlo MA; Urowitz MB; Weber HM; Houpt JB
    Ann Rheum Dis; 1966 Nov; 25(6 Suppl):673-80. PubMed ID: 5958697
    [No Abstract]   [Full Text] [Related]  

  • 30. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies with allopurinol (HPP) in patients with tophaceous gout.
    Smyth CJ
    Arthritis Rheum; 1965 Oct; 8(5):907-10. PubMed ID: 5323684
    [No Abstract]   [Full Text] [Related]  

  • 32. Allopurinol in treatment of gout.
    Scott JT; Hall AP; Grahame R
    Br Med J; 1966 Aug; 2(5509):321-7. PubMed ID: 5920652
    [No Abstract]   [Full Text] [Related]  

  • 33. Biochemical evidence for a distinct type of primary gout.
    Sorensen LB; Benke PJ
    Nature; 1967 Mar; 213(5081):1122-3. PubMed ID: 6029792
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
    Komoriya K; Osada Y; Hasegawa M; Horiuchi H; Kondo S; Couch RC; Griffin TB
    Eur J Pharmacol; 1993 Dec; 250(3):455-60. PubMed ID: 8112406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular bases of the treatment of Lesch-Nyhan syndrome, related syndromes and common gout].
    Delbarre F; Auscher C; de Gery A; Kha-Vang-Thang
    Biochimie; 1972; 54(5):709-21. PubMed ID: 4654166
    [No Abstract]   [Full Text] [Related]  

  • 36. A quantitative study of skeletal-muscle purines and pyrazolo(3,4-d)pyrimidines in gout patients treated with allopurinol.
    Watts RW; Snedden W; Parker RA
    Clin Sci; 1971 Aug; 41(2):153-8. PubMed ID: 5564305
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of allopurinol in preventing hyperuricemia in leukemia and lymphoma.
    Krakoff IH
    Cancer; 1966 Nov; 19(11):1489-96. PubMed ID: 5925255
    [No Abstract]   [Full Text] [Related]  

  • 38. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allopurinol in the treatment of gout.
    Seebach LM
    J Lancet; 1967 Oct; 87(10):411-4. PubMed ID: 6077619
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of gouty purine metabolism disorder with mercapto-pyrazolo-pyrimidine (thiopurinol)].
    Delbarre F; Auscher C; de Gery A; Brouilhet H; Olivier JL
    Presse Med (1893); 1968 Dec; 76(49):2329. PubMed ID: 5737251
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.